 |
ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update
Jul 22, 2014
|
15.5 KB |
|
| |
Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy
Increased applications of RheoSwitch® platform and its unique capabilities into targeted cellular oncology products
Phase I trial utilizing Ad-RTS-...
|
|
ZIOPHARM Oncology to Present at the 9th Annual JMP Securities Healthcare Conference
Jun 18, 2014
|
6.6 KB |
|
| |
BOSTON, June 18, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25th, 2014 at 1...
|
|
ZIOPHARM Announces Oral Presentation Highlighting Ad-RTS-IL-12 Results Correlated With Reducing Cancer Stem Cells in the Brain at ASGCT 17th Annual Meeting
May 22, 2014
|
11.0 KB |
|
| |
BOSTON, May 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other precl...
|
|
ZIOPHARM Reports First-Quarter 2014 Financial Results and Reviews Recent Activities
May 8, 2014
|
14.3 KB |
|
| |
BOSTON, May 8, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2014, and provided an update on the company's product development activities.
"ZIOPHARM, together with our channel partner Intrexon Corporation, continues to advance a portfolio of immuno-oncology...
|
|
ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer
Apr 8, 2014
|
10.6 KB |
|
| |
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine ...
|
|
ZIOPHARM Oncology to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
Mar 20, 2014
|
6.6 KB |
|
| |
BOSTON, March 20, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 21st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28th, 2014 at 3:00 p.m. ET at the Millennium Broadway Hotel...
|
|
ZIOPHARM Reports Fourth-Quarter and Full-Year 2013 Financial Results and Reviews Recent Activities
Mar 3, 2014
|
16.4 KB |
|
| |
BOSTON, March 3, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the company's product development activities.
"Working with our partner Intrexon Corporation, we made extensive progress in 2013 toward expanding...
|
|
ZIOPHARM Oncology to Present at the 16th Annual BIO CEO & Investor Conference
Feb 3, 2014
|
9.2 KB |
|
| |
BOSTON, Feb. 3, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th, 2014 at 10:00 ...
|
|
ZIOPHARM Oncology to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Jan 8, 2014
|
9.2 KB |
|
| |
BOSTON, Jan. 8, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2014 at 11:30 a.m. PT at The Westin St. Francis in San Francisco, CA.
To access a live audio webca...
|
|
ZIOPHARM Reports Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-12
Dec 7, 2013
|
13.5 KB |
|
| |
Potent biological activity observed in injected and non-injected lesionsFindings presented at Melanoma Bridge 2013 ConferenceConference Call Scheduled for 8:00 am EST on Monday, December 9
BOSTON, Dec. 7, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced positive interim results from its ongoing Phase 1/2 study of A...
|
|
ZIOPHARM Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval for Phase 1 Study of Ad-RTS-IL-12 in Subjects With Recurrent or Progressive Glioblastoma
Dec 6, 2013
|
11.4 KB |
|
| |
BOSTON, Dec. 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral...
|
|
ZIOPHARM Oncology to Present at the 25th Annual Piper Jaffray Healthcare Conference
Nov 27, 2013
|
9.1 KB |
|
| |
BOSTON, Nov. 27, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3rd, 2013 at 10:30 a.m. ET at The New York Palace Hotel in New York City.
To access a live audio webca...
|
|
ZIOPHARM Oncology Prices Public Offering of Common Stock
Oct 24, 2013
|
10.0 KB |
|
| |
BOSTON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of its previously announced public offering of 14,300,000 shares of its common stock at a public offering price of $3.50 per share. All of the shares in the offering are being sold by ZIOPHARM. The offering is expected to close on October 29,...
|
|
Mesoblast, Intrexon and ZIOPHARM to Target Cancers
Oct 23, 2013
|
15.2 KB |
|
| |
MELBOURNE, Australia, GERMANTOWN, Md. and BOSTON, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB), a world leader in the development of cell-based biologic products, Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and develo...
|
|
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock
Oct 22, 2013
|
10.0 KB |
|
| |
BOSTON, Oct. 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to commence an underwritten public offering of $50,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM.
J.P. Morgan Securities LLC will act as sole book-running manager for the ...
|
|
ZIOPHARM Announces Third Quarter Financial Results and Updates Key Development Activities
Oct 22, 2013
|
14.2 KB |
|
| |
BOSTON, Oct. 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the third quarter ended September 30, 2013, and provided an update on the Company's key development activities.
"Together with channel partner Intrexon Corporation, ZIOPHARM has begun to elucidate the broad scope of our gene exp...
|
|
ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Regulated Gene Expression System in Tumor-Homing Mesenchymal Stem Cells
Oct 22, 2013
|
51.0 KB |
|
| |
BOSTON and GERMANTOWN, Md., Oct. 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of a preclinical study demonstrating the potential for...
|
|
ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Versatility of Novel Gene Expression and Control Technology
Oct 21, 2013
|
57.4 KB |
|
| |
BOSTON and GERMANTOWN, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of preclinical data from three studies that highlight ...
|
|
ZIOPHARM and Intrexon Announce Presentations at the 2013 AACR-NCI-EORTC International Conference
Oct 17, 2013
|
18.3 KB |
|
| |
BOSTON and GERMANTOWN, Md., Oct. 17, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced scheduled poster presentations at the 2013 AACR-NCI-EORTC International...
|
|
ZIOPHARM Oncology to Present at the 12th Annual BIO Investor Forum
Oct 2, 2013
|
11.0 KB |
|
| |
BOSTON, Oct. 2, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 12th Annual BIO Investor Forum on Tuesday, October 8th, 2013 at 9:30 a.m. PT at The Palace Hotel in San Francisco, CA.
To access a live webcast of the presentation, please ...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
